Post hoc analysis of ADAPT AF-DES in patients with AF and drug-eluting stents: in the 376 aged ≥75, NOAC monotherapy vs NOAC plus clopidogrel had fewer 1-year net adverse clinical events (9.8% vs 22.3%; HR 0.37); no difference under 75; interaction non-significant.
Secondary analysisn = 960
Lee et al. Antithrombotic strategy according to age in patients with atrial fibrillation and drug-eluting stents: a post hoc analysis of the ADAPT AF-DES randomised trial